16
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Epidemiology and Health Impacts of Neuroendocrine Tumors

      Submit here before August 30, 2024

      About Neuroendocrinology: 3.2 Impact Factor I 8.3 CiteScore I 1.009 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Morphine-Induced Suppression of Cytotoxic T Lymphocyte Activity in Alloimmunized Mice Is Not Mediated through a Naltrindole-Sensitive Delta Opioid Receptor

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of chronic morphine exposure on natural killer (NK) activity in vivo and the generation of cytotoxic T lymphocytes (CTLs) in vitro and in vivo was investigated. Chronic exposure to morphine (10<sup>–5</sup>–10<sup>–11</sup> M) in vitro had no effect on the generation of antigen-driven effector cells. However, the daily administration of morphine (50.0 mg/kg, s.c.) into alloimmunized mice (C57BL/6 into C3H/HeN) for 11 days resulted in a decrease in peritoneal and splenic CTL activity but not splenic NK activity. In addition, there was a 60% decrease in the number of thymocytes recovered from chronic morphine-treated mice compared to vehicle-treated controls. However, the overall percentage of CD4+CD8-, CD4-CD8+ and CD4+CD8+ thymocytes did not change between the two groups of treated animals. Pretreatment of the mice with the δ<sub>1</sub>-selective antagonist, (E)-7-benzylidine-7-dihydronaltrexone (BNTX, 0.6 mg/kg, s.c.) did not block morphine-mediated suppression of splenic CTL activity but did block morphine-induced suppression of peritoneal lymphocyte CTL activity. In addition, BNTX pretreatment alone augmented splenic NK activity and such augmentation was blocked following chronic morphine exposure. In contrast, the 5-selective antagonist, naltrindole (20.0 mg/kg, s.c), had no effect alone nor antagonized the action of morphine on CTL activity. Splenic CTL effector cells from either treated group of animals lysed their target (EL-4 lymphoma) through a Ca<sup>2+</sup>-dependent mechanism. Collectively, the results indicate morphine suppresses CTL activity through an indirect pathway, insensitive to naltrindole rather than through direct lymphocyte opioid receptors.

          Related collections

          Author and article information

          Journal
          NIM
          Neuroimmunomodulation
          10.1159/issn.1021-7401
          Neuroimmunomodulation
          S. Karger AG
          1021-7401
          1423-0216
          1995
          1995
          22 May 1995
          : 2
          : 1
          : 44-53
          Affiliations
          Department of Microbiology, Immunology and Parasitology, Stanley S. Scott Cancer Center, LSU Medical Center, New Orleans, La., USA
          Article
          96847 Neuroimmunomodulation 1995;2:44–53
          10.1159/000096847
          7614260
          60f58c9f-0b8a-4741-ac5c-bc176e7d518a
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 10
          Categories
          Original Paper

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Naltrindole,Cytotoxic T lymphocyte,Morphine,Opioid receptor,Natural killer activity,BNTX

          Comments

          Comment on this article